KFDA likely to ban sibutramine-based drugs

Published: 2010-10-12 07:00:00

Updated: 2010-10-12 07:00:00

The Korea Food and Drug Administration (KFDA), which reaffirmed the safety and distribution of sibutramine-based drugs in July, announced its plan on October 9 to review the substance once again after much criticism arose regarding lax monitoring. On October 13, the meeting will decide whether Ko...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK